Display options
Cite
Toubiana J, Courtine E, Tores F, et al. Association of REL polymorphisms and outcome of patients with septic shock. Ann Intensive Care. 2016;6(1):28doi: 10.1186/s13613-016-0130-z.
Toubiana, J., Courtine, E., Tores, F., Asfar, P., Daubin, C., Rousseau, C., Ouaaz, F., Marin, N., Cariou, A., Chiche, J. D., & Mira, J. P. (2016). Association of REL polymorphisms and outcome of patients with septic shock. Annals of intensive care, 6(1), 28. https://doi.org/10.1186/s13613-016-0130-z
Toubiana, Julie, et al. "Association of REL polymorphisms and outcome of patients with septic shock." Annals of intensive care vol. 6,1 (2016): 28. doi: https://doi.org/10.1186/s13613-016-0130-z
Toubiana J, Courtine E, Tores F, Asfar P, Daubin C, Rousseau C, Ouaaz F, Marin N, Cariou A, Chiche JD, Mira JP. Association of REL polymorphisms and outcome of patients with septic shock. Ann Intensive Care. 2016 Dec;6(1):28. doi: 10.1186/s13613-016-0130-z. Epub 2016 Apr 08. PMID: 27059500; PMCID: PMC4826362.
Copy Download .nbib Format: NLM
Share it on

Ann Intensive Care. 2016 Dec;6(1):28. doi: 10.1186/s13613-016-0130-z. Epub 2016 Apr 08.

Association of REL polymorphisms and outcome of patients with septic shock.

Annals of intensive care

Julie Toubiana, Emilie Courtine, Frederic Tores, Pierre Asfar, Cédric Daubin, Christophe Rousseau, Fatah Ouaaz, Nathalie Marin, Alain Cariou, Jean-Daniel Chiche, Jean-Paul Mira

Affiliations

  1. Medical School, Paris Descartes University, Paris, France. [email protected].
  2. INSERM U1016, CNRS UMR 8104, Cochin Institute, Paris, France. [email protected].
  3. Department of Pediatric and Infectious Diseases, Necker University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. [email protected].
  4. Medical School, Paris Descartes University, Paris, France.
  5. INSERM U1016, CNRS UMR 8104, Cochin Institute, Paris, France.
  6. Bioinformatics Platform, Institut Imagine, Paris Descartes University- Sorbonne Paris Cité, 75015, Paris, France.
  7. Medical Intensive Care Unit, Angers University Hospital, Angers, France.
  8. Medical Intensive Care, Caen University Hospital, Caen, France.
  9. Intensive Care Unit, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

PMID: 27059500 PMCID: PMC4826362 DOI: 10.1186/s13613-016-0130-z

Abstract

BACKGROUND: cRel, a subunit of NF-κB, is implicated in the inflammatory response observed in autoimmune disease. Hence, knocked-out mice for cRel had a significantly higher mortality, providing new and important functions of cRel in the physiopathology of septic shock. Whether genetic variants in the human REL gene are associated with severity of septic shock is unknown.

METHODS: We genotyped a population of 1040 ICU patients with septic shock and 855 ICU controls for two known polymorphisms of REL; REL rs842647 and REL rs13031237. Outcome of patients according to the presence of REL variant alleles was compared.

RESULTS: The distribution of REL variant alleles was not significantly different between patients and controls. Among the septic shock group, REL rs13031237*T minor allele was not associated with worse outcome. In contrast, REL rs842647*G minor allele was significantly associated with more multi-organ failure and early death [OR 1.4; 95 % CI (1.02-1.8)].

CONCLUSION: In a large ICU population, we report a significant clinical association between a variation in the human REL gene and severity and mortality of septic shock, suggesting for the first time a new insight into the role of cRel in response to infection in humans.

Keywords: Genetics; Mortality; Multi-organ dysfunction syndrome; Polymorphism; REL; Septic shock; cRel

References

  1. Cell Immunol. 2002 May-Jun;217(1-2):47-57 - PubMed
  2. Nat Genet. 2010 Dec;42(12):1126-30 - PubMed
  3. J Immunol. 2011 Dec 1;187(11):5636-44 - PubMed
  4. Infect Immun. 2011 May;79(5):1848-54 - PubMed
  5. J Clin Invest. 2002 Sep;110(6):843-50 - PubMed
  6. Cancer Discov. 2014 May;4(5):578-91 - PubMed
  7. J Immunol. 2002 Mar 15;168(6):2590-4 - PubMed
  8. Crit Care Med. 2002 Aug;30(8):1772-7 - PubMed
  9. Arch Intern Med. 2002 May 13;162(9):1028-32 - PubMed
  10. JAMA. 1995 Sep 27;274(12):968-74 - PubMed
  11. Intensive Care Med. 2013 Feb;39(2):165-228 - PubMed
  12. Am J Respir Crit Care Med. 2008 Oct 1;178(7):710-20 - PubMed
  13. Am J Hum Genet. 2008 May;82(5):1202-10 - PubMed
  14. Cytokine. 2011 Dec;56(3):564-72 - PubMed
  15. J Clin Invest. 1997 Sep 1;100(5):972-85 - PubMed
  16. EMBO J. 1996 Dec 16;15(24):7099-107 - PubMed
  17. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1335-41 - PubMed
  18. Am J Respir Crit Care Med. 2007 Jul 15;176(2):181-7 - PubMed
  19. Heredity (Edinb). 2005 Sep;95(3):221-7 - PubMed
  20. Lancet. 2005 Oct 8;366(9493):1315-23 - PubMed
  21. J Immunol. 2011 Feb 15;186(4):2321-8 - PubMed
  22. J Exp Med. 1998 Apr 6;187(7):973-84 - PubMed
  23. PLoS One. 2011;6(11):e26920 - PubMed
  24. Int Immunol. 1999 Sep;11(9):1431-9 - PubMed
  25. J Biol Chem. 2011 Dec 30;286(52):44750-63 - PubMed
  26. Nat Genet. 2010 Apr;42(4):332-7 - PubMed
  27. Crit Care Med. 2004 Mar;32(3):858-73 - PubMed
  28. Nat Genet. 2009 Jul;41(7):820-3 - PubMed
  29. Lancet Respir Med. 2015 Jan;3(1):53-60 - PubMed
  30. J Immunol. 2010 Aug 15;185(4):2350-9 - PubMed
  31. Crit Care Med. 2010 Dec;38(12):2287-94 - PubMed
  32. Nat Genet. 2010 Nov;42(11):985-90 - PubMed
  33. Chest. 1992 Jun;101(6):1644-55 - PubMed
  34. Crit Care Med. 2007 Oct;35(10):2395-401 - PubMed
  35. J Clin Invest. 2000 Jun;105(12):1799-806 - PubMed
  36. N Engl J Med. 2013 Nov 21;369(21):2063 - PubMed
  37. Hepatology. 2011 Jun;53(6):1977-85 - PubMed
  38. Nat Genet. 2007 Apr;39(4):523-8 - PubMed
  39. Nat Genet. 2009 Feb;41(2):216-20 - PubMed
  40. J Immunol. 2007 Jun 1;178(11):7097-109 - PubMed
  41. Genes Cancer. 2011 Jul;2(7):695-711 - PubMed
  42. J Exp Med. 2003 Nov 17;198(10):1563-72 - PubMed
  43. Br J Dermatol. 2013 Apr;168(4):864-6 - PubMed
  44. Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645 - PubMed
  45. Nat Genet. 2010 Jun;42(6):508-14 - PubMed
  46. Immunol Cell Biol. 2011 Jan;89(1):27-32 - PubMed
  47. Trends Immunol. 2004 Jun;25(6):280-8 - PubMed
  48. Mol Cell Biol. 1995 Jun;15(6):3100-9 - PubMed
  49. Nat Rev Drug Discov. 2004 Jan;3(1):17-26 - PubMed
  50. Virulence. 2014 Jan 1;5(1):4-11 - PubMed
  51. Gut. 2009 Aug;58(8):1078-83 - PubMed
  52. Infect Immun. 2000 Apr;68(4):1942-5 - PubMed
  53. Ann Rheum Dis. 2010 Aug;69(8):1572-3 - PubMed

Publication Types